APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial
dc.contributor.author | Sun, G. | |
dc.contributor.author | Davies, J.R. | |
dc.contributor.author | Mell, T. | |
dc.contributor.author | Harland, M. | |
dc.contributor.author | Saleh, R.M.H. | |
dc.contributor.author | Race, Amanda D. | |
dc.contributor.author | Loadman, Paul | |
dc.contributor.author | Williams, E.A. | |
dc.contributor.author | Minihane, A.M. | |
dc.contributor.author | Hull, M.A. | |
dc.date.accessioned | 2024-08-29T08:12:53Z | |
dc.date.accessioned | 2024-08-30T11:24:11Z | |
dc.date.available | 2024-08-29T08:12:53Z | |
dc.date.available | 2024-08-30T11:24:11Z | |
dc.date.issued | 2024-02 | |
dc.identifier.citation | Sun G, Davies JR, Mell T et al (2024) APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial. Prostaglandins, Leukotrienes and Essential Fatty Acids. 201: 102623. | en_US |
dc.identifier.uri | http://hdl.handle.net/10454/19979 | |
dc.description | Yes | en_US |
dc.description.abstract | Introduction: We examined the relationship between Apolipoprotein E (APOE) genotype and n-3 highly unsaturated fatty acid (HUFA) levels in participants of the seAFOod trial, who were undergoing colonoscopy surveillance after removal of colorectal polyps. Methods: Baseline and on-treatment (eicosapentaenoic acid [EPA] 2 g daily or placebo for 6 months) levels of n-3 HUFAs, and plasma 18-hydroxyeicosapentaenoic acid (HEPE), were analysed according to APOE genotype (based on polymorphisms rs429358 and rs7412) in 584 participants. Results: Before treatment, APOE2/2 individuals had lower levels, and APOE4/4 participants had higher levels, of n-3 HUFAs, including EPA, than APOE3/3 counterparts (P < 0.01 for the APOE2/2 versus APOE4/4 comparison). After EPA supplementation, n-3 HUFA levels were not significantly different when stratified by APOE genotype, although APOE4 carriers displayed lower plasma 18-HEPE levels than individuals without an APOE4 allele (P = 0.002). Conclusions: APOE genotype is associated with differential n-3 HUFA and 18-HEPE levels in individuals with multiple colorectal polyps. | en_US |
dc.description.sponsorship | This project (NIHR128210) was funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed in this publication are those of the authors and not necessarily those of the MRC, NIHR or the Department of Health and Social Care. MAH is a NIHR Senior Investigator. MAH is supported by Cancer Research UK grant C23434/A24939. | en_US |
dc.language | en | |
dc.language.iso | en | en_US |
dc.rights | © 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | en_US |
dc.subject | Apolipoprotein E | en_US |
dc.subject | Colorectal polyp | en_US |
dc.subject | Highly unsaturated fatty acid | en_US |
dc.subject | Oxylipin | en_US |
dc.subject | Single nucleotide polymorphism | en_US |
dc.title | APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial | en_US |
dc.status.refereed | Yes | en_US |
dc.date.application | 2024-05-31 | |
dc.type | Article | en_US |
dc.type.version | Published version | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.plefa.2024.102623 | en_US |
dc.rights.license | CC-BY | en_US |
dc.date.updated | 2024-08-29T08:12:55Z | |
refterms.dateFOA | 2024-08-30T11:25:24Z | |
dc.openaccess.status | openAccess | en_US |
dc.date.accepted | 2024-05-22 |